Pluripotency and Reprogramming Symposium

When: May 24, 2019, 9:00 am - 6:00 pm
Where: Broad Institute, 415 Main Street, Cambridge, MA

Our second symposium will feature world leaders who will describe their latest advances in stem cell biology and reprogramming.

Human ​pluripotent ​stem ​cells ​possess ​the ​ability ​to ​self ​renew ​in ​vitro ​while ​maintaining ​a ​developmental ​plasticity ​that ​is ​ similar ​to ​that ​exhibited ​by ​progenitor ​cells ​of ​the ​very​ early ​embryo. ​As ​a ​result, ​pluripotent ​stem ​cells ​may ​provide ​ an ​inexhaustible ​supply ​of ​any ​differentiated ​cell ​type ​for ​both ​in ​vitro ​studies ​of ​disease ​and ​regenerative ​medicine. The ​discovery ​of ​reprogramming ​methods ​that ​rely ​on ​defined ​transcription ​factors ​and ​their ​use ​in ​the ​derivation ​of ​patient-specific ​iPS ​cell ​lines ​have ​greatly ​expanded ​the​ potential ​utility ​of ​pluripotent ​cells. ​Patient-specific ​iPS cells ​have ​already ​enabled ​in ​vitro ​studies ​of ​diseases ​ including ​spinal muscular ​atrophy, ​familial ​dysautonomia ​and​ LEOPARD ​syndrome. ​Future ​applications ​of ​human ​pluripotent ​stem cell ​lines ​could ​also ​include ​the ​study ​of ​common ​diseases ​that ​arise ​as ​the ​result ​of ​complex ​interactions ​between ​a​ patient’s ​genotype ​and ​their ​environment. ​Finally, ​pluripotent ​cells ​will ​eventually ​serve ​as ​a ​renewable ​source ​of ​both autologous ​cells ​and ​tissue ​for ​transplantation ​and ​regenerative ​medicine. Our second symposium will feature world leaders who will describe their latest advances in stem cell biology and reprogramming.

Learn more »

Connect With Us

Blog Facebook LinkedIn Twitter